Home / Research library / hGH Fragment 176-191
hGH Fragment 176-191: molecular data, studies & sources
hGH Fragment 176-191 is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.
Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review
Molecular formula, weight & structure
- Molecular formula (MF)
- C80H127N23O24S2
- Molecular weight (MW)
- 1859.1 g/mol
- PubChem compound ID
- 172966176
- Record title
- HGH Fragment 176-191
Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.
Source: PubChem CID 172966176 · retrieved 2026-09-21
Chemical identifiers and source data
- IUPAC name
- acetic acid;(2S)-2-[[2-[[(4R,7S,13S,16S,19S,22S,25R)-25-[[(2S)-5-amino-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]amino]-22-(3-carbamimidamidopropyl)-13-(2-carboxyethyl)-7,19-bis(hydroxymethyl)-6,9,12,15,18,21,24-heptaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23-heptazacyclohexacosane-4-carbonyl]amino]acetyl]amino]-3-phenylpropanoic acid
- InChIKey
- OFBOQPIYGYREOZ-LWAQQTRHSA-N
- SMILES
- CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CCCNC(=N)N)CO)C(C)C)CCC(=O)O)CO)C(=O)NCC(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CC=CC=C3)N.CC(=O)O
Identifiers & sequence
- PubChem CID
- 172966176
- InChIKey
- OFBOQPIYGYREOZ-LWAQQTRHSA-N
Peptide sequence · 16 residues (one-letter code; X marks a residue without a one-letter code)
FLRIVQCRSVEGSCGF
Condensed notation with terminal groups and non-standard residues
H-Phe-Leu-Arg-Ile-Val-Gln-Cys(1)-Arg-Ser-Val-Glu-Gly-Ser-Cys(1)-Gly-Phe-OH.CH3CO2H
Source: PubChem Biologic Line Notation. A reference sequence for the record, not an analysis of a supplied batch.
Calculated molecular descriptors
| Monoisotopic (exact) mass | 1857.8866 Da |
|---|---|
| Heavy atoms | 129 |
| Hydrogen-bond donors | 28 |
| Hydrogen-bond acceptors | 26 |
| Rotatable bonds | 43 |
| Topological polar surface area | 781.8 Ų |
| Calculated logP (Crippen) | -7.05 |
| Rings | 3 |
| Stereocenters | 15 |
| Formal charge | 0 |
Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.
Registered clinical trials
Studies registered on ClinicalTrials.gov that list hGH fragment 176-191 as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.
No registered study naming this compound was matched. This is a documented gap in registry coverage, not proof that no study exists.
Registry check 2026-10-01 · Run this search on ClinicalTrials.gov
Human intervention studies
Selected studies in which participants received hGH fragment 176-191, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.
No human study that administered this compound was retained in this selected bibliography. This is a documented evidence gap in our selection, not proof that no study exists.
Preclinical research, reviews & other publications
Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.
No additional matching publication was retained. The search links below allow further investigation; they are not evidence that a study exists.
hGH Fragment 176-191 supplier sources
Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.
hGH Fragment 176-191 for sale: compare prices, sizes and forms from every tracked supplier →
| Supplier | Recorded packages | Example source listing |
|---|---|---|
| Amino USAUSD | 5mg Vial1 recorded offers | 5mg Vial · $65.00Checked Nov 6, 2026Supplier listing, hGH Fragment 176-191 5mg Vial, Amino USA, opens in a new tab |
| Cenexa LabsUSD | 5mg Vial1 recorded offers | 5mg Vial · $68.99Checked Nov 6, 2026Supplier listing, hGH Fragment 176-191 5mg Vial, Cenexa Labs, opens in a new tab |
Reference sources & further reading
- PubChem compound record 172966176 — chemical identity and structure.
- Wikipedia: HGH Fragment 176–191 — Background encyclopedia; not a primary clinical source.
The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.
Search for additional research
These links run searches; their results have not been individually reviewed and can include unrelated compounds.
Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.
Related research profiles
ACE-031
Molecular identity needs further verification
3 selected publications · 2 human intervention studies · 4 registered trials
Adipotide
C111H206N36O28S2
2557.2 g/mol · PubChem CID 163360068
1 selected publication · 0 human intervention studies
AICAR
C9H14N4O5
258.23 g/mol · PubChem CID 17513
4 selected publications · 3 human intervention studies · 4 registered trials
Small molecule · highest stage: Phase 3
B7-33
Molecular identity needs further verification
4 selected publications · 0 human intervention studies
BAM15 Capsules
Molecular identity needs further verification
8 selected publications · 0 human intervention studies
Dermorphin
C40H50N8O10
802.9 g/mol · PubChem CID 5485199
1 selected publication · 1 human intervention study